If incorrect enrollment isn’t on your short list of operational risks, it should be.
Once an ineligible participant is enrolled, the consequences cascade across safety, data credibility, timelines and cost. The FDA’s December 2024 guidance classifies incorrect enrollment as an “important protocol deviation” and instructs sponsors to be proactive in prevention, without providing operational solutions.
Centralized eligibility review has emerged as a practical strategy that ensures every participant meets inclusion and exclusion criteria, eliminating enrollment-based protocol deviations and enhancing protection of trial integrity and patient welfare.
Why FDA guidance shines a light on eligibility
The FDA’s 2024 guidance emphasizes the need for a consistent system to identify, document, assess and report protocol deviations. It also reinforces quality-by-design approaches like simplifying protocols where possible, allowing appropriate operational flexibility and building controls into study processes up front.
The guidance distinguishes important deviations from all others, defining “important” as having the potential to significantly affect either the reliability of study data or a participant’s rights, safety or wellbeing. Incorrect enrollment can carry both types of impact, which is why it’s classified as an important protocol deviation and likely why it’s used so prominently as an example throughout the guidance.
For global trials, the hard part is identifying adequate controls and making them work in the real world.
Designing centralized eligibility for real world global operations
In global trials, centralized eligibility succeeds or fails based on thoughtful planning for operational realities:
Regional differences
Country mix matters. It is important to understand local practice patterns, data availability, and documentation standards by region. These factors can affect whether sites can realistically supply the required information within your target timelines.
Dependencies on sites, labs, imaging, and translation services
Turnaround times for data and document availability must align with eligibility windows. Clear expectations, expedited pathways and an experienced and dedicated data coordination team help preserve momentum.
Reviewer capacity and management
When engaging eligibility reviewers for your trial, it is important to assess reviewer capacity and availability compared to the expected volume of work. For small trials, one or two reviewers might suffice. Larger or more complex programs may require a larger number of committee members.
Process design for centralized eligibility is like finely tuned choreography. Detailed upfront planning is essential. Each person in the process must know their own steps. They must also understand how their steps factor into the overall dance. Everyone must move in coordinated step with everyone else.
Here’s what it looks like in practice.
A workflow for centralized eligibility review
At its core, centralized eligibility review is a systematic way to confirm eligibility up front, using source evidence and consistent documentation.
- Site submissions and source evidence: Sites receive clear instructions on required documentation, such as source documents from the patient chart, imaging, and pathology. They submit eligibility packages into the centralized workflow.
- Operational completeness check: A coordination team verifies all required documents are present and logically mapped to protocol criteria. Any gaps are addressed before the package is sent for medical review.
- Independent medical review: One or more independent medical reviewers assess the eligibility package. This review may be performed by an external committee or the Sponsor’s or CRO’s medical monitors.
- Decision communication and archiving: Final eligibility decisions are communicated back to sites promptly, with clear determinations and relevant comments. All documentation is archived in an inspection-ready format with full audit trails.
This structured process provides consistent, unbiased, centralized review of eligibility. It standardizes enrollment decisions, ensuring that every enrolled patient has documented evidence that demonstrates adherence to protocol inclusion-exclusion criteria. As a result, it eliminates enrollment-based protocol deviations without creating enrollment delays.
Core KPIs that show centralized eligibility is working
Track these KPIs across the eligibility process, coordination team and reviewer decision-making to monitor speed, quality and impact:
- Turnaround time from initial submission to final eligibility decision
- Number and percentage of patients deemed ineligible due to centralized eligibility review
- Actual number of enrollment-based protocol deviations despite centralized eligibility review
- Percentage of cases requiring rework or resubmission
- Inter-/Intra-reviewer agreement rates
Used consistently, these metrics help teams keep the process running smoothly, with on-time, high quality eligibility decisions.
The role of technology in centralized eligibility review
With manual eligibility processes, there is a lot of friction, and the process is prone to pitfalls including delays, data loss and other failure points.
A technology‑enabled approach makes these challenges solvable. With a process management platform, it is possible to scale centralized eligibility review and keep it from becoming a bottleneck.
One unified workspace
Platforms like Judi bring stakeholders, documents, data, communication and decisions into one place. Process stakeholders receive the data and documents they need at the right time at the right point of their journey along the path of the workflow, and the entire process is conducted with full traceability for audit readiness. This eliminates the friction that comes from reliance on fragmented document collection, uncontrolled processes and manual tracking through spreadsheets, email, and multiple portals.
Built-for-purpose eligibility workflow
Judi offers a streamlined, proven workflow to support the needs and complexities of the eligibility decision-making process. The workflow has three simple steps. It starts with a site request in the platform for medical review. Next, the eligibility data coordinator works with the site to compile an accurate, focused and complete electronic eligibility package. Finally, an eligibility reviewer provides their eligibility decision online after review of the package. This makes it easy to obtain complex medical decisions.
Automation for expedited cycle‑time and enhanced quality and compliance
Automated tracking, routing, and notifications reduce manual work. AI-assisted redaction further reduces manual work and enhances quality by scanning source documents to identify un-redacted PHI/PII that has not already been redacted by the site. 21 CFR Part 11, HIPAA and GDPR compliance provide the system-driven due diligence needed for clinical trial conduct. Audit trails and version control capture what was reviewed and how decisions were made. These features drive efficiency throughout every step of the process.
Together, structured process and workflow technology reduce eligibility risk without slowing enrollment.
Aligning with FDA guidance, and what to do next
The FDA’s December 2024 guidance reinforces quality-by-design by encouraging teams to build controls into study execution to prevent protocol deviations, including incorrect enrollment. Centralized eligibility review is one practical way to do that. When designed well, it supports consistent, unbiased, rapid eligibility decisions across sites and regions, with the documentation and traceability teams need for audit readiness.
Watch the full webinar here for practical guidance and real‑world examples of centralized eligibility review in action.
